Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

March 12, 2020March 12, 2020

Roche Suspends Phase 1 Trial Testing Tominersen (RG6042) for Huntington’s

News

A Phase 1 clinical trial testing Roche’s investigational therapy tominersen for Huntington’s disease has been placed on hold after two cases of infection were found during the study. The infections ... Read more

March 10, 2020March 10, 2020

Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds

Huntington's Disease News, News

The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still ... Read more

March 10, 2020March 10, 2020

UniQure Presents More Data Supporting the Effectiveness of Gene Therapy Candidate AMT-130

News

New preclinical data continues to support uniQure’s AMT-130 investigational gene therapy for Huntington’s disease. Results reveal the therapy lowered the levels of toxic huntingtin protein in nerve cells derived from ... Read more

January 30, 2020January 30, 2020

Rexulti Eases Motor and Psychiatric Symptoms of Huntington’s, Case Report Shows

News

Rexulti (brexpiprazole), an antipsychotic medicine approved for schizophrenia and in some cases depression, eases motor and psychiatric symptoms of Huntington’s disease, according to a case study. The study, “Effectiveness ... Read more

January 28, 2020January 28, 2020

UniQure’s Gene Therapy AMT-130 for Huntington’s Shows Promising Results in Preclinical Studies

News

AMT-130, uniQure’s experimental gene therapy candidate for Huntington’s disease, halts shrinkage of certain brain regions and helps preserve cognitive function in a mouse model of the disease, preclinical data ... Read more

December 17, 2019December 17, 2019

MicroRNA May Help Prevent Buildup of Toxic Proteins in Huntington’s Disease, Study Shows

News

A small RNA molecule known as microRNA-1, found in both worm and human cells, can promote the removal of toxic protein aggregates — hallmarks of neurodegenerative diseases — by ... Read more

October 31, 2019October 31, 2019

MC10 and University of Vermont Establish Partnership to Study Gait Impairment in Huntington’s, other Movement Disorders

News

MC10 and the University of Vermont have teamed up to advance understanding of gait impairments in Huntington’s disease and other movement disorders. The partnership will combine MC10’s BioStamp nPoint ... Read more

October 3, 2019October 3, 2019

Nmnat Enzyme May Halt Accumulation of Mutant Htt Protein Clumps in Nerve Cells, Study Shows

News

Increasing the levels of a natural enzyme called nicotinamide mononucleotide adenylyltransferase — or Nmnat — halts the formation of mutant huntingtin (Htt) protein aggregates that build up in nerves ... Read more

July 23, 2019July 23, 2019

Phase 2 Trial Recruiting Early-stage Huntington’s Patients to Test Neflamapimod for Improving Cognition

News

EIP Pharma is launching a proof-of-concept Phase 2 clinical trial to assess the ability of therapeutic candidate neflamapimod to treat cognitive dysfunction in patients with early-stage Huntington’s disease. The ... Read more

July 18, 2019July 18, 2019

Cannabinoid Derivatives Show Therapeutic Potential in Mouse Model, But EHP-102 Still Superior

News

Emerald Health Pharmaceuticals announced that two of its cannabinoid-derived candidates — CBGA-Q and CBGA-Q-Na Salt — showed anti-inflammatory and neuroprotective effects in a mouse model of Huntington’s disease. However, ... Read more

Pin It on Pinterest